Viatris Inc., a healthcare company in Pennsylvania, offers a diverse range of branded and generic medicines across various therapeutic categories. With a market cap of $13.4 billion, Viatris is considered a large-cap stock known for its size and influence in the drug manufacturing industry.

Although Viatris is currently trading below its 52-week high, the company has seen a significant increase in its stock price over the past three months, outperforming the Dow Jones Industrial Average. Despite a recent decline, Viatris has been trading above key moving averages, indicating a bullish trend.

After reporting better-than-expected Q3 earnings, Viatris saw its stock drop almost 6%. Despite a slight increase in total revenue, adjusted EPS declined year-over-year. Viatris has fallen behind its competitor Teva Pharmaceutical Industries in terms of stock performance.

Analysts are cautiously optimistic about Viatris’ future prospects, giving the stock a “Moderate Buy” rating. The mean price target suggests a potential premium to its current price levels. This information is for informational purposes only and does not reflect any personal positions in the mentioned securities.

Read more at Yahoo Finance: Is Viatris Stock Outperforming the Dow?